Scientists Just Dosed the First Human With a Gene Therapy That Reverses Cellular Aging

· hermez's blog

July 30, 2026 · Tags: aging, gene therapy, vision, epigenetics, biotechnology

For the first time, a therapy designed to reverse a root cause of aging has entered human testing. It's not a pill or a supplement — it's an injection of a reprogrammed virus into the eye, and it's targeting two forms of progressive blindness.

The therapy is called ER-100, and the first patient received it in June 2026. This is a big deal not just for eye disease, but for the entire field of aging biology.

As we age, a specific type of neuron in the eye — retinal ganglion cells, or RGCs — starts dying off. These are the cells that connect your retina to your brain. When they go, your visual field shrinks inward from the edges. Eventually, everything goes dark.

There are currently no treatments that can bring those cells back once they're gone.

One of the main drivers of this cell death is something called epigenetic noise. Over decades, methyl groups accumulate on DNA like static on old magnetic tape. They corrupt the instructions that tell RGCs how to function. The cells don't necessarily die from damage — they lose the ability to read their own operating manual.

The bet: cells aren't destroyed, just silenced #

A group of researchers at Harvard, led by David Sinclair, have been working on a different way of thinking about this problem. Their bet is that aging RGCs aren't permanently destroyed — the epigenetic information that makes them function is still there, just buried under layers of methylation. If you could strip those methyl groups off, the cell might return to a younger, functional state.

The approach is called partial epigenetic reprogramming, and it's based on something called Yamanaka factors — a set of transcription factors discovered in 2006 that can turn any adult cell back into a stem cell. That discovery won Shinya Yamanaka a Nobel Prize.

The full Yamanaka cocktail uses four factors: OCT4, SOX2, KLF4, and c-MYC. But c-MYC is an oncogene — it causes tumors. So Sinclair's team removed it. Three factors (OSK) are enough to partially rewind the cell's age without turning it all the way back into a stem cell, which would also risk cancer.

How ER-100 works #

ER-100 is built from a modified virus. Specifically, an adeno-associated virus (AAV) with its pathogenic DNA stripped out. In its place, researchers inserted genes for OCT4, SOX2, and KLF4.

The vector is injected directly into the eye, where it infects retinal ganglion cells and delivers its payload. Once inside, those three proteins activate the cell's own TET enzymes. TET1 and TET2 physically move along the DNA strand and clip off methyl groups one by one, restoring the cell to a more youthful gene expression pattern.

But there's a catch. Push too hard and the neuron forgets it's a neuron, reverting into a stem cell and potentially forming a tumor. To prevent this, the three genes are engineered with a safety switch. They're only active when the patient takes a common antibiotic called doxycycline. Stop the antibiotic, the therapy turns off. This lets clinicians pulse the treatment — enough to restore function without pushing past the point of no return.

The evidence so far #

The foundational study, published in Nature in 2020, tested OSK reprogramming in mice with optic nerve damage. In 12-month-old mice, RGC survival after injury increased from roughly 18% in untreated animals to 54% in treated ones — a threefold improvement.

A follow-up study in 2023 ran the experiment for a full year. Mice with glaucoma-induced vision loss recovered to healthy levels within two months of treatment. The improvements held for 11 months with continuous OSK expression. No tumors formed, even after 21 months of continuous treatment.

Life Biosciences, the company that developed ER-100 (Sinclair is a co-founder), also ran preclinical studies in non-human primates — a much better model for human translation than mice. The company reports improvements in visual function, axon structure, and DNA methylation patterns in treated animals.

The clinical trial #

The Phase 1 trial (NCT07290244) began recruiting in March 2026. It's a first-in-human safety study, enrolling up to 18 patients with two conditions: open-angle glaucoma (OAG) and non-arteritic anterior ischemic optic neuropathy (NAION).

OAG is the most common form of glaucoma, where optic nerve damage accumulates over years from elevated pressure inside the eye. NAION is a sudden, painless loss of vision from interrupted blood flow — no approved treatments exist. Both conditions lead to RGC death and permanent vision loss.

Patients receive a single intravitreal injection into one eye, followed by eight weeks of oral doxycycline to activate the therapy. Primary completion is expected in May 2027, with full study completion in 2032.

This is a safety trial, not an efficacy trial. The goal is to answer one question: is it safe to put these reprogramming factors in a human eye? If yes, larger trials can test whether it actually works.

Why this matters beyond eyes #

The eye is a smart place to test cellular rejuvenation. It's small, self-contained, and easy to monitor. Success or failure is measurable — you can literally watch the retina respond.

But if partial epigenetic reprogramming works in one tissue, there's reason to believe it could work in others. In 2024, a separate study showed that systemic OSK gene therapy extended median remaining lifespan in aged mice by 109%. Treated animals not only lived longer — they showed improved frailty scores and reversed epigenetic age in the liver and heart.

That doesn't mean ER-100 will cure aging. It means the underlying biology might be more reversible than we thought. The epigenetic information that makes cells function properly doesn't seem to be permanently lost with age — it's just inaccessible. If you can restore access, function may follow.

Sources #

last updated: